A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium.
Transgenic mice expressing the human superoxide dismutase 1 (SOD-1) mutant at position 93 (G93A) develop a phenotype resembling amyotrophic lateral sclerosis (ALS). In fact, G93A mice develop progressive motor deficits which finally lead to motor palsy and death. This is due to the progressive degeneration of motor neurons in the ventral horn of the spinal cord. Although a similar loss is reported for specific cranial motor nuclei, only a few studies so far investigated degeneration in a few brainstem nuclei. We recently reported that chronic lithium administration delays onset and duration of the disease, while reducing degeneration of spinal motor neuron. In the present study, we extended this investigation to all somatic motor nuclei of the brain stem in the G93A mice and we evaluated whether analogous protective effects induced by lithium in the spinal cord were present at the brain stem level. We found that all motor but the oculomotor nuclei were markedly degenerated in G93A mice, and chronic treatment with lithium significantly attenuated neurodegeneration in the trigeminal, facial, ambiguus, and hypoglossal nuclei. Moreover, in the hypoglossal nucleus, we found that recurrent collaterals were markedly lost in G93A mice while they were rescued by chronic lithium administration.
Ferrucci
Michela
M
Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy.
Spalloni
Alida
A
Bartalucci
Alessia
A
Cantafora
Emanuela
E
Fulceri
Federica
F
Nutini
Michele
M
Longone
Patrizia
P
Paparelli
Antonio
A
Fornai
Francesco
F
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000818:Animals; D001369:Axons / Q000187:drug effects / Q000473:pathology; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001931:Brain Mapping / Q000379:methods; D001933:Brain Stem / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002795:Choline O-Acetyltransferase / Q000032:analysis / Q000378:metabolism; D003391:Cranial Nerves / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D019610:Cytoprotection / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005154:Facial Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007002:Hypoglossal Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009046:Motor Neurons / Q000378:metabolism* / Q000473:pathology; D009410:Nerve Degeneration / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D014276:Trigeminal Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D014630:Vagus Nerve / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
D015415:Biomarkers; D018696:Neuroprotective Agents; D008094:Lithium; D002795:Choline O-Acetyltransferase